Amarin Corporation PLC
AMRN15.380USD
+0.220+1.45%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
319.44MValor de mercado
PerdaP/L TTM
Mais detalhes de Amarin Corporation PLC Empresa
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Informações da empresa
Código da empresaAMRN
Nome da EmpresaAmarin Corporation PLC
Data de listagemApr 01, 1993
CEOMr. Aaron D. Berg
Número de funcionários275
Tipo de títulosDepository Receipt
Fim do ano fiscalApr 01
EndereçoWeWork One Central Plaza Dame Street
CidadeDUBLIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIreland
Código postalD02 K7K5
Telefone35316699020
Sitehttps://amarincorp.com/
Código da empresaAMRN
Data de listagemApr 01, 1993
CEOMr. Aaron D. Berg
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 23 de jul
Atualizado em: qua, 23 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
3.00%
Acadian Asset Management LLC
0.92%
Eversept Partners, LP
0.82%
Two Sigma Investments, LP
0.79%
Other
88.47%
Investidores
Investidores
Proporção
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
3.00%
Acadian Asset Management LLC
0.92%
Eversept Partners, LP
0.82%
Two Sigma Investments, LP
0.79%
Other
88.47%
Tipos de investidores
Investidores
Proporção
Hedge Fund
11.52%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
1.67%
Research Firm
0.96%
Individual Investor
0.95%
Pension Fund
0.14%
Family Office
0.10%
Bank and Trust
0.01%
Venture Capital
0.01%
Other
81.27%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
335
3.85M
18.62%
-1.48M
2025Q1
349
5.67M
20.22%
+144.25K
2024Q4
362
81.89M
19.91%
-21.31M
2024Q3
365
76.69M
18.66%
-50.88M
2024Q2
389
87.45M
21.29%
-59.57M
2024Q1
405
98.68M
24.03%
-57.40M
2023Q4
423
103.82M
25.42%
-56.37M
2023Q3
447
95.61M
23.44%
-78.96M
2023Q2
464
107.90M
26.46%
-89.05M
2023Q1
492
118.85M
29.19%
-104.01M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Sarissa Capital Management, L.P.
1.24M
6%
--
--
Mar 31, 2025
Kynam Capital Management LP
620.73K
3%
--
--
Mar 31, 2025
Acadian Asset Management LLC
189.58K
0.92%
+100.29K
+112.31%
Mar 31, 2025
Eversept Partners, LP
169.96K
0.82%
+94.13K
+124.13%
Mar 31, 2025
Two Sigma Investments, LP
162.85K
0.79%
-33.32K
-16.99%
Mar 31, 2025
WaterFront Wealth, Inc.
125.73K
0.61%
+1.64K
+1.32%
Mar 31, 2025
SCP Investment, LP
125.00K
0.6%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
116.05K
0.56%
-87.42K
-42.96%
Mar 31, 2025
Longitude (Cayman) Ltd
81.00K
0.39%
-37.50K
-31.65%
Dec 31, 2024
Berg (Aaron D.)
80.71K
0.39%
+36.64K
+83.12%
Jun 26, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
AltShares Event-Driven ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
SPDR S&P International Small Cap ETF
Proporção0.01%
SPDR Portfolio Developed World ex-US ETF
Proporção0%
Global X Aging Population ETF
Proporção0%
ActivePassive International Equity ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
AltShares Event-Driven ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 12, 2025
Merger
20<1
Data
Tipo
Proporção
Mar 12, 2025
Merger
20<1
